Octreotide Scan (Somatostatin Receptor Imaging):what to expect

Your doctor may request an octreotide scan to:

• Locate a suspected neuroendocrine tumour in someone with characteristic symptoms or hormone elevations.
• Stage a known neuroendocrine tumour and find unsuspected metastases.
• Decide whether a tumour is likely to respond to somatostatin-analogue treatment (octreotide / lanreotide) or peptide receptor radionuclide therapy (PRRT).
• Follow up a treated neuroendocrine tumour to look for recurrence.
• Evaluate certain other tumours that express somatostatin receptors — paragangliomas, phaeochromocytomas, medullary thyroid cancer, some lymphomas.

Wherever the tracer accumulates above background, the scan suggests cells expressing somatostatin receptors. Most often this means:

• A neuroendocrine tumour — primary tumour, lymph nodes, liver metastases, bone metastases.
• Normal tissues that express receptors — pituitary gland, thyroid, spleen, kidneys, bladder. These are recognised by the reading physician and not mistaken for disease.
• Inflammation — occasionally, areas of active inflammation can also take up tracer; clinical context is used to interpret these.

A negative scan in a setting where neuroendocrine disease is strongly suspected does not entirely rule out disease — some neuroendocrine tumours, particularly higher-grade ones, lose their somatostatin receptors and become difficult to see on this test.

The scan itself is painless. The only physical discomfort is the needle prick for the tracer injection. The gamma camera moves over you while you lie still on the imaging table — many patients find the longer scans tedious but not uncomfortable.

• Somatostatin-analogue treatment can affect uptake and scan timing, but withholding intervals are not universal and must be balanced against symptom control. Never stop or delay octreotide, lanreotide, or another cancer treatment without explicit instructions from the treating and imaging teams.
• Hydrate well in the 24 hours before each visit.
• No fasting is required.
• Bring previous imaging (CT, MRI, prior nuclear scans).
• Tell the team if there is any chance of pregnancy.
• Tell the team if you are breastfeeding and obtain written radiopharmaceutical-specific instructions before injection.

A conventional octreotide scan is performed over two days:

Day 1 (injection day):

• A small needle is placed in a vein in your arm.
• The radioactive tracer (typically Indium-111 pentetreotide) is injected.
• You can usually go home and continue normal activities while the tracer distributes.
• Initial images may be taken at 4 hours.

Day 2 (imaging day):

• You return 18 to 24 hours after the injection.
• The gamma camera takes whole-body images, sometimes with additional SPECT or SPECT/CT images of specific areas.
• Total imaging time is usually 1 to 2 hours.

Some centers add a Day 3 imaging session for delayed views if needed.

A DOTATATE PET/CT version, when available, is done in a single 2 to 3 hour visit and is generally faster and more sensitive.

Iodinated contrast is not inherent to the nuclear-medicine acquisition, although a diagnostic contrast CT may sometimes be added. Food, hydration, bowel preparation, and medicine instructions vary, so follow the center's protocol.

A nuclear medicine physician usually reads the study within 1 to 2 working days. The formal report typically reaches your doctor within 3 to 5 working days. Urgent cases can be expedited.

If the scan shows somatostatin-receptor-positive disease:

• The location and extent of disease guide treatment.
• Many patients with positive scans benefit from somatostatin-analogue therapy (octreotide LAR or lanreotide injections) to control symptoms and slow growth.
• Patients with widespread receptor-positive disease may be candidates for peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTATATE — a treatment that delivers therapeutic radiation directly to receptor-expressing tumour cells.
• Surgery, ablation, or chemotherapy may still be considered depending on the overall picture.

Nuclear medicine shows physiology and tracer uptake, but uptake is not always specific to one disease and spatial detail may be lower than CT or MRI. Inflammation, infection, treatment effects, medicines, blood glucose, recent imaging, movement, and the timing of images can change a result. A normal scan does not exclude every abnormality, and an abnormal focus may need correlation with CT, MRI, ultrasound, laboratory tests, biopsy, or follow-up imaging.

Preparation and radiation precautions are radiopharmaceutical- and protocol-specific. Tell the department before the tracer is given if you are or may be pregnant, are breastfeeding, care for a young child, or recently had another nuclear-medicine test. Do not stop medicines, fast, interrupt breastfeeding, or follow a fixed distancing period based only on a general webpage; obtain written instructions for the exact tracer, activity, and examination from the nuclear-medicine team.

• RadiologyInfo.org: General nuclear medicine
• RadiologyInfo.org: Preparing for a nuclear-medicine examination
• IAEA: Basics of quality management for nuclear medicine practices

An octreotide scan is the established whole-body imaging test for neuroendocrine tumours, capable of finding receptor-positive disease that is invisible on routine CT or MRI. The two-day protocol is longer than most nuclear medicine tests, but the diagnostic information is uniquely valuable for staging, treatment selection, and follow-up. Where available, DOTATATE PET/CT is the more sensitive modern equivalent and is increasingly the first-line test.